Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 11; 155(2):201-206.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antineoplastic Agents
Antineoplastic Agents
Bevacizumab
Bevacizumab
Disease Progression
Disease Progression
Disease-Free Survival
Disease-Free Survival
Female
Female
Humans
Humans
Middle Aged
Middle Aged
Molecular Targeted Therapy
Molecular Targeted Therapy
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Ovarian Neoplasms
Ovarian Neoplasms
Platinum Compounds
Platinum Compounds
Retrospective Studies
Retrospective Studies
Treatment Outcome
Treatment Outcome
authors with profiles
Abby Rose Rubenstein
Kai Ding
Lauren E Dockery